Moolec Science (MLECW) Change in Account Payables (2022 - 2024)
Moolec Science (MLECW) posted Change in Account Payables of $688172.0 for Q4 2024, up 198.14% sequentially from -$701192.0 in Q3 2024, and up 122.48% YoY from $309324.0 in Q1 2024.
Moolec Science (MLECW) Change in Account Payables (2022 - 2024) Analysis & Trends
Moolec Science has reported Change in Account Payables for 3 years, with the latest figure at $688172.0 in Q4 2024.
- Quarterly Change in Account Payables rose 122.48% year-over-year to $688172.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $19.0 million (up 163.06% YoY) and the FY2025 annual result came in at -$18.8 million, down 215.73% from the prior year.
- Change in Account Payables climbed to $688172.0 in Q4 2024 per MLECW's latest filing, from -$701192.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $20.4 million in Q2 2024 and troughed at -$3.1 million in Q4 2023.
- A 3-year average of $2.6 million and a median of $199325.5 in 2022 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 2172.21% in 2023, down 10790.07% in 2023.
- Over 3 years, Change in Account Payables stood at $4.1 million in 2022, then sank by 175.45% to -$3.1 million in 2023, then soared by 122.48% to $688172.0 in 2024.
- According to Business Quant data, Change in Account Payables over the past three periods registered $688172.0, -$701192.0, and $20.4 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 688,172.00 |
| Dec 31, 2024 | 688,172.00 |
| Sep 30, 2024 | -701,192.00 |
| Sep 30, 2024 | -701,192.00 |
| Jun 30, 2024 | 20.44 Mn |
| Jun 30, 2024 | 20.44 Mn |
| Mar 31, 2024 | -1.39 Mn |
| Mar 31, 2024 | -1.39 Mn |
| Dec 31, 2023 | -3.06 Mn |
| Dec 31, 2023 | -3.06 Mn |
| Sep 30, 2023 | 292,432.00 |
| Sep 30, 2023 | 292,432.00 |
| Jun 30, 2023 | 12.93 Mn |
| Jun 30, 2023 | 12.93 Mn |
| Mar 31, 2023 | -2.92 Mn |
| Mar 31, 2023 | -2.92 Mn |
| Dec 31, 2022 | 4.06 Mn |
| Dec 31, 2022 | 4.06 Mn |
| Sep 30, 2022 | 106,219.00 |
| Sep 30, 2022 | 106,219.00 |